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Schizophrenia is commonly considered a neurodevelop-
mental disorder that is associated with significant mor-
bidity; however, unlike other neurodevelopmental disor-
ders, the symptoms of schizophrenia often do not manifest
for decades. In most patients, the formal onset of schizo-
phrenia is preceded by prodromal symptoms, including
positive symptoms, mood symptoms, cognitive symptoms,
and social withdrawal. The proximal events that trigger
the formal onset of schizophrenia are not clear but may
include developmental biological events and environmen-
tal interactions or stressors. Treatment with antipsychotic
drugs clearly ameliorates psychotic symptoms, and main-
tenance therapy may prevent the occurrence of relapse.
The use of atypical antipsychotic agents may additionally
ameliorate the pathophysiology of schizophrenia and pre-
vent disease progression. Moreover, if treated properly
early in the course of illness, many patients can experience
a significant remission of their symptoms and are capable
of a high level of recovery following the initial episode.
Because the clinical deterioration that occurs in schizo-
phrenia may actually begin in the prepsychotic phase,
early identification and intervention may favorably alter
the course and outcome of schizophrenia. Biol Psychia-
try 2001;50:884–897 © 2001 Society of Biological
Psychiatry
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Introduction
Schizophrenia is widely considered to be a geneticallymediated neurodevelopmental disorder. The neurode-
velopmental theory of schizophrenia postulates that etio-
logic and pathogenic factors occurring long before the
formal onset of the illness (probably in gestation) disrupt
the course of normal neural development, resulting in
subtle alterations of specific neurons and circuits, which
confer vulnerability and may ultimately lead to malfunc-
tion (Figure 1) (Bloom 1993; Lewis and Lieberman 2000;
Murray and Lewis 1987; Weinberger 1987). The conse-
quences of these neurodevelopmental aberrations, how-
ever, do not immediately cause clinical manifestations in
schizophrenia as in other neurodevelopmental disorders,
such as autism, fragile X, or Down’s syndrome. Rather,
symptoms typically present after a latency period of 1–3
decades. At the same time, high-risk and longitudinal birth
cohort studies have identified social, motor, and cognitive
dysfunctions and mild physical anomalies during child-
hood and adolescence, before the onset of illness (Jones
1997). These features, however, are mild in severity and
have low predictive validity as individual markers of
schizophrenia (Erlenmeyer-Kimling and Cornblatt 1987;
Fish 1977).
Clinical Course of Schizophrenia
The onset of the formal symptoms of schizophrenia is
generally preceded by a prodromal phase. So-called pro-
dromal symptoms and behaviors (i.e., those that herald the
approaching onset of the illness) include attenuated posi-
tive symptoms (i.e., illusions, ideas of reference, magical
thinking, superstitiousness), mood symptoms (i.e., anxi-
ety, dysphoria, irritability), cognitive symptoms (i.e., dis-
tractibility, concentration difficulties), social withdrawal,
or obsessive behaviors to name a few (McGlashan 1996).
Because many of these prodromal phenomena extensively
overlap with the range of mental experiences and behav-
iors of persons in the ages of risk who do not subsequently
develop schizophrenia, prodromal symptoms cannot be
considered diagnostic. It is precisely their nonspecificity
and lack of high predictive validity that limits their utility
for the purposes of early intervention (Gottesman and
Erlenmeyer-Kimling 2001; Schaffner and McGorry 2001).
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The development of frank psychotic symptoms marks
the formal onset of first- episode schizophrenia, although
this is usually not diagnosed for some time until the patient
seeks or is brought to medical attention. Indeed, the
duration of psychotic symptoms before diagnosis and
treatment averages about 1 year, and if time from first
appearance of prodromal symptoms is considered the
average duration is about 3 years (McGlashan 1996).
Despite this, most individuals recover symptomatically
from the first episode; however, the majority of patients
proceed to have one or more subsequent episodes in the
form of psychotic relapses from which some proportion
fail to recover, at least to the same degree as they had
during their first or prior episode (Lieberman et al 1993,
1996; Robinson et al 1999b). This process of psychotic
relapses, treatment failure, and incomplete recovery leads
many patients to a chronic course of illness, and persistent
disturbances and deficits in perceptions, thought pro-
cesses, and cognition (Lieberman 1999; McGlashan
1988). In this way, patients accumulate morbidity in the
form of residual or persistent symptoms and decrements in
function from their premorbid status. The process of
accruing morbidity in the context of exacerbations and
(relative) remissions has been attributed to progression of
the illness (Kraepelin 1919) and described as “clinical
deterioration” (Bleuler 1980).
Interestingly, although the majority of patients with
schizophrenia exhibit this pattern of deterioration, this
occurs to different degrees and different temporal se-
quences in the illness. Despite this variation, the deterio-
ration process predominantly occurs in the early phases of
the illness—in the prepsychotic prodromal period and
Figure 1. Clinical and pathophysiologic course of schizophrenia. This diagram attempts to integrate and schematically depict the
clinical and pathophysiologic course of schizophrenia in its various clinical stages. To orient the reader starting from the top row:
Developmental Stage describes the stage of life during which the various events and phenomena occur; Clinical Signs and Symptoms
refers to the mental and behavioral manifestations of the illness; Stage of Illness describes all premorbid and morbid phases of the
illness; Pathologic Process refers the hypothesized pathogenic and pathophysiologic mechanisms that underlie and are causal to the
clinical manifestations of the disorder; Developmental Process and Events indicates the neurobiologic maturational processes and
environmental events that may unmask or destabilize the neural circuits made vulnerable by etiologic and pathogenic factors. DA,
dopamine; NMDA, N-methyl-D-aspartate; Glu, glutamate.
Pathogenesis and Course of Schizophrenia 885BIOL PSYCHIATRY
2001;50:884–897
during the first 5–10 years after the initial episode (Figure
1). Following this, the illness stabilizes and, although there
may be subsequent exacerbations, there is no continued
illness-driven decline in functioning and increase in resid-
ual symptoms (although the most severe variants may con-
tinue to decline through senescence [Harvey et al 1999]).
Measures of Vulnerability and
Pathophysiology
Schizophrenia emerges over time, and the illness can be
conceptualized as having three pathophysiologic stages,
which correspond to distinct clinical stages: neurodevel-
opmental (premorbid) stage, neuroplastic (prodromal, on-
set, and deteriorative) stage, and neuroprogressive (dete-
riorative and chronic/residual) stage (Table 1) (Lieberman
et al 1997).
Measures of Vulnerability
It is well established that having a first-degree relative
with a psychotic disorder increases risk of developing
schizophrenia and related psychotic disorders (Gottesman
1991). Prenatal or birth complications (i.e., hypoxia,
infection, toxic exposure) also are associated with in-
creased risk for schizophrenia (Buka and Fan 1999;
Cannon et al 2000). Although specific genes and epige-
netic factors (i.e., occurring during gestation and birth) are
believed to confer vulnerability for the development of
schizophrenia, there are no clear and specific manifesta-
tions by which at-risk persons can be identified. High-risk
and longitudinal birth cohort studies have identified sev-
eral premorbid factors that indicate increased risk for
schizophrenia, including family history, prenatal and peri-
natal complications, body dysmorphias, and mild premor-
bid deficits in social, motor, and cognitive functions
during childhood and adolescence (Jones 1997). For ex-
ample, subtle motor abnormalities during infancy (Walker
and Lewine 1990) and deficits in social functioning,
organizational ability, and intellectual functioning at ages
16–17 years have been associated with the later appear-
ance of schizophrenia (Davidson et al 1999). In addition,
individuals with schizophrenia have subtle but measurable
Table 1. Clinical and Pathologic Stages of Schizophrenia
Illness stage Developmental stage Clinical features Pathophysiological process Treatment
Premorbid Gestation, infancy,
childhood, early
adolescence
Mild physical anomalies,
poor motor coordination,
mild cognitive
impairments, social
deficits
Neurodevelopmental:
inductive, patterning, and
synaptogenetic anomalies
None proven;
potential for gene
therapy
Prodromal Adolescence and
early adulthood
Nonspecific mood
symptoms: anxiety,
sadness, lability,
irritability; sleep
disturbances; cognitive
impairment in attention,
concentration; mild
psychotic symptoms:
illusions, suspiciousness,
magical thinking;
behavioral changes:
substance use, social
withdrawal,
preoccupations
Maturational events
(postpubertal hormonal
effects, myelination,
synaptic regression)
interact with
developmental anomalies
to unmask vulnerabilities
to neuroplastic
dysfunction
None proven;
potential for
supportive and
stress reduction
therapies, potential
use of GABA
agonists, NMDA
allosteric
modulators,
antioxidants,
atypical
antipsychotics
Onset/deteriorative Adolescence and
early adulthood
Psychosis, cognitive
impairment, negative
symptoms, and social
deficits
Endogenous neurochemical
sensitization involving
meso-limbic-cortical-
striatal circuits mediated
by dopamine and
glutamate
Antipsychotic drugs
proven efficacy;
potential use of
neuroprotective
agents
Chronic/residual Adulthood, middle
age, senescence
Negative symptoms,
cognitive impairment,
social deficits, and
psychosis
Neuroprogression with
limited neurotoxicity,
loss of cell processes,
possible induction of
apoptosis of cortical-
limbic striatal neurons.
Antipsychotics
proven but limited
efficacy; potential
for use of
experimental
agents as adjuncts
Table 1 describes the hypothesized pathologic stages of schizophrenia from a developmental, clinical, and pathophysiological perspective and the corresponding
therapeutic strategies currently utilized or considered. The prodromal stage is transitional from the premorbid to the onset/deteriorative phase.
GABA, -aminobutyric acid; NMDA, N-methyl-D-aspartate.
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body dysmorphias, particularly of body structures that are
derived from neural crest tissue and develop during the
late first and second trimesters of fetal life (Maynard et al,
2001; Waddington et al 1999). All of these features,
however, are mild in severity and have low predictive
validity as individual markers.
Studies of individuals at risk for schizophrenia (such as
first-degree relatives and individuals with schizotypal
personality disorders) and first-episode patients have
found that information processing deficits are one of the
earliest clinical and cognitive markers of vulnerability for
schizophrenia (Carter et al 1997; Nuechterlein and Daw-
son 1984; Nuechterlein et al, 1991, 1994; Pert et al 1992;
Posner 1988; Weiss et al 1992). Attention deficits are
present before the onset of the illness, and the clinical
expression of the illness in high-risk adolescents (Corn-
blatt and Keilp 1994). Executive function impairments,
including working memory, are also consistently demon-
strated in patients with schizophrenia, as well as those with
schizophrenia-spectrum disorders (Goldberg and Gold
1995). Although attention and executive function deficits
have been associated with prefrontal cortical pathology in
schizophrenia, other information processing deficits sug-
gest a significant breakdown in hippocampal and temporal
cortical functions.
Neurophysiologic studies of patients with schizophrenia
have revealed abnormal auditory information selection
processes during oddball tasks. These deficits have been
found as early as the initial sensory processing stage of
information, and suggest that sensory gating and attention
deficits are core components of the pathophysiology of
schizophrenia (Adler et al 1982; Boutros and Belger
1999). The observation of decreased P50 suppression in
over half of the first-degree relatives of schizophrenic
patients (Siegel et al 1984) suggests that P50 may be a
vulnerability marker for schizophrenia and schizotypal
personality disorder (Cadenhead et al 2000; Clementz et al
1998; Siegel et al 1984; Waldo et al 1991).
Recently, in utero ultrasonography was used to examine
the brain structure in high-risk fetuses and showed that
high-risk fetuses exhibited enlarged lateral ventricles com-
pared with matched normal fetuses (Gilmore et al 2000).
This evidence suggests that a genetic developmental dia-
thesis of vulnerability for schizophrenia manifest in brain
morphology is present long before the onset of symptoms
and is reflected by characteristic features that are neither
severe nor always specific.
Neuropathology of Schizophrenia
The proximal events that trigger the formal onset of
schizophrenia are not known but may include normal
neurobiologic maturational processes (i.e., experience-
dependent axonal and dendritic proliferation, programmed
cell death, axonal myelination, synaptic pruning) and
environmental interactions, including gestational insults,
trauma, stress, and substance abuse. This suggests the
possibility that schizophrenia is unmasked or provoked by
developmental biological events and/or environmental
perturbations (Lieberman et al 1997; Weinberger 1987).
Evidence for a progressive, as well as a developmental,
component to the illness is derived from recent neuroim-
aging studies in first-episode patients. These studies have
found evidence of neuroanatomical changes at first treat-
ment contact, as well as evidence of limited neuroanatomi-
cal progression. Comparisons of studies evaluating
chronic patients with the few available studies of recent
onset or first-episode patients with schizophrenia have
revealed somewhat greater rates of morphologic abnor-
malities (reflected in the number of regions affected and
the size of volume differences) in older and chronic
patients (Bogerts et al 1993; Lieberman et al 1992).
Progression of neuropathology is suggested by the
cross-sectional brain imaging studies that show that chron-
ically ill schizophrenic patients have more numerous and
severe structural brain abnormalities compared with first-
episode patients; however, prospective imaging studies
provide the most direct test of whether there is progression
or stasis of brain abnormalities in schizophrenic patients.
Three prospective studies of first-episode patients (DeLisi
et al 1992, 1995, 1997; Gur et al 1998; Lieberman et al
1996, 2001) and five prospective studies of chronic
patients (Davis et al 1998; Garver et al 1997; Gur et al
1998; Mathalon et al 2001; Rapoport et al 1999) have
examined the progression of structural brain abnormalities
and/or the relationship of progression to clinical course in
patients with schizophrenia. These studies have produced
mixed findings, but generally suggest that a subset of
patients with poor treatment outcome or a more severe
course are more likely to show progressive changes in
brain morphology, with ventricular enlargement and cor-
tical gray matter volume reductions as the most consistent
findings. Some investigators have also found a negative
correlation between patient compliance with antipsychotic
medications and morphologic changes, suggesting that use
of antipsychotics may slow disease progression in some
patients (DeLisi et al 1992, 1995, 1997; Lieberman et al
2001; Nair et al 1997). There is also convincing evidence
that patients with treatment-refractory childhood onset and
geriatric schizophrenic patients have progressive ventric-
ular enlargement (Davis et al 1998; Rappaport et al 1999).
Proton magnetic resonance spectroscopy (1H MRS) is
used to measure compounds such as N-acetylaspartate
(NAA), which is a neuronal marker that reflects cell
number and density (Stanley et al 1995b). Most 1H MRS
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studies, as well as postmortem studies, of patients with
schizophrenia have shown reductions in NAA in either the
frontal or temporal lobes (Akbarian et al 1993a, 1993;
Bertolino et al 1996b; Buckley et al 1994; Choe et al 1994;
Fukuzako et al 1995; Maier et al 1995; Nasrallah et al
1994; Renshaw et al 1995; Shioiri et al 1996; Yurgelun-
Todd et al 1996), with some exceptions (Bartha et al 1997;
Stanley et al 1996).
There is increasing evidence that NAA is a metaboli-
cally active metabolite that is influenced by pharmaco-
logic treatment as well as disease state (Vion-Dury et al
1995). Bertolino et al (1996a) reported a highly significant
effect of antipsychotic treatment in increasing the concen-
tration of NAA in the dorsolateral prefrontal cortex
(DLPFC) of patients with schizophrenia. Antipsychotic
medications affect the concentration and activity of gluta-
mate in the prefrontal cortex (Stanley et al 1996). There-
fore, increases in NAA in the DLPFC associated with
antipsychotic treatment may be mediated by increases in
glutamate in this region.
Using 1H MRS and 31P MRS, investigators have found
that patients with schizophrenia exhibit differences in the
concentrations of NAA and various phosphomonoester
(PME) and phosphodiester (PDE) moieties in specific
brain regions, including the temporal and prefrontal cor-
tex. N-acetylaspartate is an abundant amino acid located in
neuronal cell bodies and processes. The PMEs are phos-
pholipids involved in membrane synthesis, and PDEs are
byproducts of lipid metabolism that are believed to reflect
membrane turnover. Thus, these biochemical measures
can be used to indirectly assess neuronal and glial mass,
integrity, and turnover, which may reflect pathophysio-
logic processes. Investigators have found that NAA is
consistently reduced in the temporal cortex in patients
with schizophrenia (including first-episode patients), but
less consistently so in other brain regions, notably the
prefrontal cortex (Keshavan et al 2000). There have been
no reports of longitudinal 1H MRS studies of NAA.
31P MRS studies of first-episode patients have described
reduced concentrations of PMEs and elevated levels of
PDEs primarily in the prefrontal cortex, suggesting in-
creased phospholipid metabolism, possibly due to mem-
brane turnover in response to a pathologic process, such as
excessive synaptic pruning (Keshavan et al 1994; Pet-
tegrew et al 1991; Stanley et al 1995b). Stanley et al
(1995a) found that PMEs were generally lower in patients
with schizophrenia at all stages of the illness, but PDEs
were elevated in first-episode patients, perhaps reflecting a
more fulminant process during that stage.
In another study of patients with schizophrenia in
various stages of illness, Stanley and coworkers, using 1H
MRS, found higher glutamine concentrations in patients
with schizophrenia compared with controls (Stanley et al
1996). In addition, glutamine concentrations were posi-
tively correlated with illness duration, and this relationship
was not associated with the effects of age or treatment.
Moreover, glutamine levels were reduced by antipsychotic
drug treatment. The role of the excitatory amino acids
(EAA), glutamate and aspartate, have been studied in
detail in various preparations and animal models of neu-
rodegeneration (Lieberman 1999). It has been proposed
that the glutamate may induce slow excitotoxic effects that
in turn induce the loss of cell processes, possibly through
apoptosis in a manner that would not induce reactive
gliosis (Jarskog et al 2000; Lieberman 1999b; Wang et al
1999). Abnormally elevated glutamine levels, therefore,
may be associated with schizophrenia and disease
progression.
Several investigators have described pathophysiologic
processes that involve or could lead to neurodegeneration.
These specifically implicate N-methyl-D-aspartate
(NMDA) receptor hypofunction and excitotoxicity (Olney
and Farber 1995), antagonism of NMDA receptors by
N-acetylaspartylglutamate (NAAG) and consequent oxi-
dative stress (Coyle and Puttfarcken 1993), reduction in
-aminobutyric acid (GABA) interneuron-mediated inhi-
bition of pyramidal neurons in the cingulate cortex (Benes
1995), and dopamine-mediated neurochemical sensitiza-
tion (Laruelle et al 1999; Lieberman et al 1997) and
neurotoxicity (Wyatt 1995) as pathogenic mechanisms
(Table 1).
Treatment Strategies to Alter Course and
Prevent Progression of Schizophrenia
Some authors have suggested that pharmacologic treat-
ment suppresses the symptoms of schizophrenia but does
not alter the course or potential progression of the disease
(Hegarty et al 1994). In contrast, others have postulated
that antipsychotic drugs ameliorate the pathophysiologic
process that causes psychotic symptoms and leads to
clinical deterioration (Jody et al 1990; Lieberman et al
1997; Wyatt 1991). Some of the most important evidence
for the latter hypothesis is derived from treatment studies
of first-episode patients and has shown associations be-
tween the duration of pretreatment psychosis and outcome
(see references in Table 2).
Specifically, many, but not all, of these studies found
that longer periods of active psychotic symptoms before
first treatment were associated with worsened outcome.
What is remarkable is that this relationship was present for
outcomes measured in multiple ways, including the time to
or level of recovery from the first episode, the time to or
likelihood of relapsing after recovery from the first epi-
sode, and long-term outcomes measured globally for up to
5 years after beginning treatment for first-episode schizo-
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Table 2. Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia
Reference Study sample Duration of illness Duration of illness and outcome
Wyatt et al 1997 25 initially nonmedicated
and 71 initially
medicated patients with
schizophrenia
DUP of initially non-medicated
subjects is about 6 mos
longer than DUP of initially
medicated subjects
The initially nonmedicated subjects
required more rehospitalization
days during year 2 after
discharge from the index
hospital admission and had
worse global functioning across
a period of 6–7 y following
index discharge
Waddington et al 1995 DUP has been regarded as a
continuous variable in a
multiple regression
analysis in 88 subjects
and as a dichotomous
variable in between-
groups comparisons of 49
short DUP (13.7 y 
11.8 y) and 39 long DUP
(21.2 y  12.9 y)
subjects
DUP: mean 17.1 y, range 0–51
Duration of illness: mean
34.6 y, SD  11.5
Longer DUP predicts more severe
negative symptoms and general
cognitive impairment at follow-
up
Scully et al 1997 52 subjects DUP: mean 13.9 y, SD  11.9
Duration of illness: mean
43.1 y, SD  10.3
Longer DUP predicts more severe
negative symptoms and general
cognitive impairment at follow-
up, DUP is not associated with
level of positive symptoms and
executive dysfunction at follow-
up
Jablensky et al 1992 78.2% of the 1379 initially
examined patients
completed 2-year follow-
up and were included in
the analysis of course
and outcome
Not reported Type of onset is a significant
predictor of a 2-year pattern of
course, % time spent in
psychotic episodes, % time
spent in complete remission, %
time spent in unimpaired social
functioning, and % time on
antipsychotic medication.
Patients with acute onset had the
most favourable outcomes,
patients with gradual onset had
the least favourable outcomes,
those with subacute onset were
in the middle
Loebel et al 1992 n  70 (54 with
schizophrenia, 16 with
schizoaffective disorder)
DUP: mean 51.9 wks, SD 
82.3 Duration of untreated
illness: mean 150.8 wks, SD
 176.6 Duration of
prodrome: Mean  98.5
wks, SD  156.6
Long DUP is associated with
longer time to remission and
lower level of remission after
first psychotic break
Robinson et al 1999a n  118 dichotomized to
long (more than 1 year)
and short (less than 1 y)
DUP groups
DUP: mean 71 wks, SD  150
Duration of untreated
illness: mean 143 wks, SD
 205
DUP is associated with treatment
response at a level of
significance p  .03
Robinson et al 1999b n  104 DUP: mean 64 wks, SD  146
Duration of untreated
illness: mean 119 wks, SD
 181
DUP of 1 y or longer does not
predict first relapse
Szymansky et al 1996 n total  70, duration of
illness (DUP for the first-
episode patients) is
analyzed as a continuous
variable
DUP of the 34 first-episode
patients: Mean 3.2 y, SD 
4.3
Longer duration of untreated
psychosis correlates with less
improvement of positive
symptoms in the first 6 mos of
neuroleptic treatment
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Table 2. (Continued)
Reference Study sample Duration of illness Duration of illness and outcome
McGorry et al 1996a
Harrigan et al 2000
200 first-episode cases with
schizophrenia,
schizophreniform,
schizoaffective, delusional
disorder, bipolar disorder
with psychotic features,
major depression with
psychotic features, brief
reactive psychosis,
induced psychosis, and
psychosis NOS
DUP total sample: mean 193.7
d, SD  615.6, median 25;
schizophrenia only: mean
1035, median 122;
schizophreniform only: mean
28.1, median 10.5;
nonschizophrenia/schizophreniform:
mean 69.7, median 14
Duration of prodrome: mean
455.7 days, SD  818.8,
median 172.5
Longer DUP is correlated with
longer duration of psychotic
symptoms at first hospitalization.
Better levels and rates of
recovery are seen with DUP 
28 d. DUP is independent
predictor of QOL at 12 mos.
Longer DUP is correlated with
more positive and negative
symptoms, and poorer global
functioning and quality of life at
12-month follow-up. DUP is an
independent predictor of 12-
month QLS, SANS negative,
and BPRS positive symptoms
Edwards et al 1998 15 prolonged recovery cases
compared to 212 non-
prolonged recovery cases
DUP in the prolonged recovery
group: mean 418.4 d,
median 153, SD  695.8 d
Association between long DUP and
treatment resistance
Haas et al 1998 n  80 with short DUP
(less than 1 y) and n 
23 with long DUP (1 y or
longer)
DUP of the short DUP group:
mean 0.6 y, SD  2.1
Duration of illness of the
short DUP group: mean 5.9
y, SD  6.9 DUP of the
long DUP group: mean 4.3
y, SD  4.0 Duration of
illness of the long DUP
group: mean 8.1 y, SD 
7.0
Long DUP is associated with more
severe negative symptoms, but
not with level of positive
symptoms on admission. Short
vs. long DUP groups did not
differ in terms of length of index
hospitalization. Long DUP is
associated with more severe
SAPS positive and SANS
negative symptoms at discharge
from index hospitalization.
Greater improvement in GAS
global functioning, from
admission to discharge, for the
short DUP group
Linszen et al 1998 n  76 dichotomized to
long (more than 1 y) and
short (less than 1 y) DUP
groups
Duration of untreated illness:
mean 5.4 mos, SD  11.0
DUP did not predict psychotic
relapse during 12-month follow-
up
Wiersma et al 1997 63 subjects with first-ever
episode of nonaffective
psychosis
Not reported The duration of the first remission
period is not predicted by mode
of onset or DUP
Larsen et al 2000 43 first-episode patients of
whom 32 had
schizophrenia, 3
schizophreniform, 1
schizoaffective disorder, 5
delusional disorder, 2
brief reactive psychosis
DUP: Mean 114, median 26
wks
Long DUP is significantly
corcorrelated with more negative
and positive symptoms and
poorer global functioning, and
poorer level of remission at 1
year
Larsen et al 1998 34 first-episode patients
with schizophrenia
divided into long (n 
17, mean 244, median
182 wks, range 52–936,
SD 203) and short (n 
17, mean 15, median 9
wks, range 1–52, SD 14)
DUP groups
DUP: mean 130 wks median
54, range 1–936, SD  203
Long DUP is associated with
deteriorating course of
premorbid functioning, weaker
social network and more social
withdrawal. DUP is not
associated with PAS total scores,
baseline GAF, and baseline
PANSS positive, negative, and
general symptoms scores
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Table 2. (Continued)
Reference Study sample Duration of illness Duration of illness and outcome
Madsen et al 1999 21 first-episode
schizophrenic patients, 10
patients with other
psychotic disorders, and 9
healthy volunteers
Not reported DUP is not associated with
nonresponsiveness to
antipsychotic medications at 5-
year follow-up. DUP is
significantly correlated with
cortical (mainly frontal) atrophy
and sulcal enlargment at baseline
as measured by CT
Craig et al 2000 For every diagnostic
category DUP was
divided into three groups
DUP: median 98 d (95% CI 
36.3-159.7) for patients with
schizophrenia/schizoaffective
disorder Median 9 d (95%
CI  5.7–12.3) for bipolar
disorder Median 22 d (95%
CI  6.6-37.4) for psychotic
depression
DUP is not associated with
remission of positive symptoms,
global functioning, and negative
symptoms at 24 mos
Hoff et al 2000 50 subjects divided into
short (n  15) and long
(n  35) DUP groups
with 1 y as the cutoff
point
DUP: mean 11.4 mos, SD 
16.2, range 1–72 Duration of
behavioral change: mean 3.4
y, SD  6.1, range 1–41
No association between DUP and
baseline MRI brain structure
volumetric measurements or
neuropsychologic summary
scores
Ho et al 2000 74 subjects, DUP is treated
as a continuous variable
DUP: mean 60.8 wks, median
13.5 SD  130.5 Duration
of untreated illness: mean
130.5 wks, SD  204.5,
median 53.5
DUP is not associated with time to
positive symptom remission.
DUP is not significantly
correlated with quality of life or
the severity of negative,
psychotic, and disorganized
symptoms at 6-month follow-up
Barnes et al 2000 53 subjects split around the
median of 26 wks into
short and long DUP
groups
DUP: mean 59 wks, median
26, SD  93 Duration of
prodrome: mean 113.5 wks,
SD  232
No difference between the short
and long DUP groups on
measures of IQ or intellectual
decline from premorbid level,
oculomotor and neurocognitive
function, psychomotor poverty,
reality distortion, and
disorganization syndrome scores
at baseline. DUP is not
associated with response to first
exposure to antipsychotic
medication as measured by the
Brenner scale (Brenner et al
1990)
Drake et al 2000 248 subjects, DUP regarded
as a continuous variable
DUP: mean 38 wks, median
12, range 4–624 16 patients
had DUP between 2 and 16 y
Longer DUP was correlated with
more positive and general
PANSS symptoms, but not with
more negative symptoms at
baseline. Longer DUP predicts
less improvement of PANSS
during 6–12 wks of treatment
Whooley et al 1997 53 subjects dichotomized
into short-term symptom
(DUP less than 1 y, n 
30) and long-term
symptom (DUP group of
1 y or longer, n  23)
groups. Patient’s report
was used for estimating
DUP
DUP per patient report: mean
22.7 mos, median 6, SD 
36.8, range 1–240 DUP per
family report: mean 15.9
mos, median 3, SD  34.5,
range 0–240
DUP is not associated with PANSS
total and syndrome scores, but
long DUP predicts significantly
poorer quality of life at baseline
evaluation
Bottlender et al 2001
(personal
communication)
58 subjects, DUP is
categorized in three
groups: 6 mos (n 
39); 6 mos and 1 y (n
 5); and 1 y (n  14)
DUP is less than 6 mos in 39
patients (67%), between 6
mos and 1y in 5 patients
(8.6%), and more than 1 y in
14 patients (24.1%)
Longer DUP is associated with
more pronounced negative,
positive, and general
psychopathological symptoms as
well as lower global functioning
15 y after first hospitalization
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phrenia. Moreover, maintenance treatment studies have
demonstrated the prophylactic effect of antipsychotic
drugs in preventing relapse. Treatment may be responsible
for mitigating the course of illness and producing more
favorable outcomes (Davis and Andriukaitis 1986). With
the advent of the second generation or atypical drugs, the
question is asked whether they have any selectively
beneficial effects that would improve outcome if used in
first episode patients (Lieberman et al 1996). Preclinical
studies suggest that antipsychotic drugs may do more than
just suppress symptoms and ameliorate the underlying
pathophysiology, forestall disease progression, and pre-
vent morbidity from increasing (Mohn et al 1999; Olney
and Farber 1995; Duncan et al 2000). Such a hypothesized
effect could be achieved in a variety of ways. On a clinical
level these drugs have superior efficacy in their rapidity
and degree of symptom remission and prevention of
relapse. Because they are better tolerated they should have
higher rates of treatment adherence, which should result in
fewer relapses. At a biologic level atypical drugs may be
more effective at alleviating the pathophysiology of
schizophrenia and may have a more efficient and effective
mechanism of action. Preclinical studies suggest a possible
basis for this hypothesized effect (Mohn et al 1999; Olney
and Farber 1995; Duncan et al 2000). Based on the
glutamate/NMDA receptor hypofunction model of schizo-
phrenia, the ability of antipsychotic drugs to alter gluta-
mate-mediated behavioral and cellular functions induced
by NMDA antagonists have been examined. These studies
show that conventional drugs can alleviate only some of
the behavioral effects of NMDA antagonists (i.e., in-
creased locomotor activity but not social isolation and
acoustic startle responses) but that they do not block the
cellular effects reflected by early immediate gene expres-
sion and uptake of 2-deoxyglucose, a marker of cellular
metabolism. Moreover, studies with an NMDA knock-
down mouse strain that only partially expresses the NR1
subunit of the NMDA receptor have demonstrated that the
atypical drug clozapine blocks the abnormal behaviors
(i.e., increased locomotor activity) at 1/40 the dose of
haloperidol (Mohn et al 1999). Several clinical studies
have also begun to examine this question. Preliminary
reports from these suggest that there may be advantages in
the use of atypical drugs that would lead to better
long-term outcomes (Emsley 1999; McEvoy et al 2000).
The theory that schizophrenia is a genetically mediated,
neurodevelopmental disorder suggested that affected indi-
viduals were “doomed from the womb” and consequently
was pessimistic as to prognosis; however, recent studies
have shown that most patients experience a substantial
reduction and even remission of psychotic symptoms
following the initial episode if treated properly early in the
course of their illness, although associated negative and
cognitive symptoms can persist (Whitesides et al 1998).
These studies also revealed that individuals suffering
first-episode psychosis experienced an alarming delay
between onset of psychotic symptoms and initiation of
treatment that averaged between 1 and 2 years (Table 2)
(McGlashan 1999).
If the pathophysiology of schizophrenia is progressive,
beginning at or before the onset of psychosis, then the
potential for prompt or even early intervention would
seem very compelling. Thus, the prospect that early
intervention favorably alters the course and outcome of
schizophrenia has exerted a powerful influence on psychi-
atric research and treatment strategies. If recovery and
improved outcomes occur with earlier treatment that
reduces the duration of active psychosis, then it is logical
to try to intervene before the onset of illness. For this
reason, the prodromal stage of schizophrenia has become
a prime target for research and development of therapeutic
strategies (McGlashan 1996; McGorry et al 1999).
Table 2. (Continued)
Reference Study sample Duration of illness Duration of illness and outcome
Black et al 2001 19 subjects categorized into
short (n  9) and long (n
 10) DUP groups split
around the median DUP
of 57 wks
DUP total sample: median 57
wks Mean short DUP group
11.28 wks, Median 8.14
Mean long DUP group 147.8
wks, median 116.6
Long DUP is associated with more
severe PANSS negative
symptoms. DUP is not
associated with PANSS positive
or total PANSS ratings. Long
DUP is associated with more
severe positive symptoms and
poorer global functioning at 6-
month follow-up
Verdoux et al 2001 65 subjects divided into
short (3 mos) and long
(3 mos) DUP groups
DUP: mean 22.7 mos, median
3, SD  59.3
Subjects with long DUP are more
likely to present with psychotic
symptoms and continuous illness
course over the 2-year follow up
period
DUP, duration of untreated psychosis; NOS, not otherwise specified; QOL, quality of life; QLS, quality of life scale; SANS, scale for the assessment of negative
symptoms; BPRS, Brief Psychiatric Rating Scale; SAPS, scale for the assessment of positive symptoms; GAS, global assessment scale; PANSS, positive and negative
syndrome scale; CT, computed tomography; MRI, magnetic resonance imaging.
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The prodromal stage is believed to be a critical juncture
in the course of schizophrenia because, not only does it
herald the onset of psychosis and the manifestations by
which the illness is diagnosed (and then treated), but
because the clinical deterioration that occurs in the early
stages of the illness may actually begin in the prepsychotic
phase (Carpenter et al 1991; Hafner et al 1998). Indeed,
the momentum toward early effective treatment interven-
tion is so great that outreach programs for early identifi-
cation and psychosis prevention services are now being
developed and evaluated worldwide (McGlashan 1996).
Although overall, this represents a substantial advance
in the attitude and approach to the clinical care of patients
with schizophrenia, this movement has stimulated many
questions and controversies (Lieberman and Fenton 2000).
Among these is the feasibility and safety of early inter-
vention, particularly with pharmacologic agents, before
the establishment of a clear diagnosis. The effectiveness of
such potentially powerful preventive strategies is depen-
dent on the soundness of the methods, the certainty with
which persons truly at risk for imminent illness can be
identified, and understanding of the potential risks and
benefits of careful watching versus preemptive treatment.
There is a critical need for a better understanding of the
natural history of the early stages of schizophrenia and
how patients progress from the prodromal stage to the
onset of psychosis.
Conclusions
There has been remarkably little study of the earliest
stages of schizophrenia and the reasons why the duration
of active first-episode psychosis is so prolonged. For
example, the actual nature and time-course by which
patients develop symptoms is largely unknown. Moreover,
whether the mode and nature of the onset differs by
gender, age of onset, or in relation to premorbid charac-
teristics (i.e., intelligence quotient). Regarding treatment,
it is not known how much of the duration of active
psychosis is accounted for by delay in patients seeking
treatment and how much is because of delay in establish-
ment of diagnosis and initiation of treatment. If it is the
former, then the question is whether this is associated with
lack of disease awareness and recognition among patients,
families, and friends. If the latter, then the question must
be asked whether patients have ready access to mental
healthcare. This is a public health problem of some
magnitude. It is not clear how knowledge, skills, attitudes,
beliefs, and barriers operate as determinants of help-
seeking in individuals experiencing symptoms or in per-
sons who notice symptoms in family members, friends, or
acquaintances, and how these factors can be modified.
Clearly, delay in seeking treatment by symptomatic pa-
tients potentially may be reduced by various measures,
including development of community outreach programs
and increasing public awareness of mental illness. Strate-
gies, such as the integration of early detection teams into
youth services in Australia (McGorry et al 1996b) and
sustained antistigma-oriented social marketing in Norway
(McGlashan 1996), are important pilot tests of innovative
models to meet this challenge.
Historically, schizophrenia has been regarded with ther-
apeutic pessimism; however, demonstration of good treat-
ment outcomes in first-episode and recent-onset patients
and the association between duration and episodes of
active psychosis with progression and outcome of the
disorder has generated efforts and hope that morbidity
may be limited and the course of illness altered by early
intervention. The advent of atypical antipsychotic drugs
may be a consequential factor in this evolving therapeutic
strategy, because their improved safety and efficacy pro-
file compared with standard neuroleptics increases the
likelihood that patients will adhere to treatment and
potentially experience improved therapeutic effects. In
addition, preliminary evidence suggests that atypical anti-
psychotics may have undefined properties that will more
efficiently ameliorate the pathophysiology of schizophre-
nia associated with psychosis and thereby prevent disease
progression; however, future studies of the onset of
schizophrenia and advances in drug discovery may lead to
new even more effective intervention and prevention
strategies.
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